Results 291 to 300 of about 262,194 (367)

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Myosteatosis as a New Risk Factor of Surgical Complications in Kidney Transplant Recipients: A Retrospective Study. [PDF]

J Cachexia Sarcopenia Muscle
Morel A, Ouamri Y, Ségaux L, Zaidan L, Moryoussef M, Mulé S, Champy CM, Reizine E, Ingels A, Luciani A, Grimbert P, Canouï-Poitrine F, Matignon M, Pigneur F, Stehlé T.   +14 more
europepmc   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

SVF-gel application for the alleviation of full-thickness skin graft contraction: an experimental study in mice. [PDF]

Sci Rep
Ni X, Xu N, Shen J, Wan X, Shen S, Lei C, Wang S, Wang B, Shan X.   +8 more
europepmc   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

Coexistence of neuroendocrine carcinoma and squamous cell carcinoma of the skin after kidney transplantation: a case report. [PDF]

Arch Craniofac Surg
Yoon W, Lee JI, Lee JH.
europepmc   +1 more source

History of organ transplantation via the two-way paradigm [PDF]

, 1999
Demetris, AJ, Murase, N, Starzl, TE
core  

Cancer risks in people on dialysis and kidney transplant recipients: a Catalan cohort study, 2003-21. [PDF]

Clin Kidney J
Oliveras L, Pareja L, Ribes J, Comas J, Couceiro C, Favà À, Codina S, Coloma A, Manonelles A, Lloberas N, Melilli E, Martinez-Carbonell E, Gálvez J, Mosteiro S, Tort J, Borràs JM, Cruzado JM, Montero N.   +17 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Ocular graft-versus-host disease: Risk factors of ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation in Denmark. [PDF]

Acta Ophthalmol
Jeppesen H.
europepmc   +1 more source